Author: admin

Paul Kirch Introduces Askology Method™ – A New Approach to Sales and Business Engagement for Entrepreneurs and Small Business Owners

Paul Kirch Introduces Askology Method™ - A New Approach to Sales and Business Engagement for Entrepreneurs and Small Business Owners

“With today’s competitive market, traditional sales tactics aren’t enough,” says Paul Kirch, founder of BOSS Academy and creator of the Askology Method™. “The key to standing out is to shift from selling to engaging. When you ask better questions, you create better opportunities.”
Paul Kirch Launches Askology Method™ to Transform Sales Conversations Sales strategist Paul Kirch introduces Askology Method™, a groundbreaking approach to engagement, networking, and sales success. Focused on asking the right questions, Askology™ helps professionals build stronger relationships, uncover real opportunities, and drive better results. Featuring 13 structured courses, the program teaches effective sales, negotiation, and communication strategies. Learn more at AskologyMethod.com.

Fort Worth, TX – February 11, 2025 – Sales and business strategist Paul Kirch has launched the Askology Method™, a powerful new approach to engagement, motivation, networking, and sales success. Designed to help professionals build stronger relationships and drive results, Askology™ focuses on the art of asking the right questions to foster deeper connections and uncover real opportunities.

Sales and business strategist Paul Kirch has launched the Askology Method™, a powerful new approach to engagement, networking, and sales success. Designed to help professionals build stronger relationships and drive results, Askology™ focuses on the art of asking the right questions to foster deeper connections and uncover real opportunities.

A Comprehensive Learning Experience:

The Askology Method™ offers a structured learning platform with 13 courses, each designed to help business professionals improve their communication, sales, and relationship-building skills. The courses include:

1. The Foundation of Askology – Learn the four core question types that drive engagement, build trust, and lead to more sales.

2. Active Listening – Learn techniues that drive deeper connections.

3. Assumptive Selling – Uncover key insights, build deeper relationships, and earn trust through better listening skills.

4. Follow-up Fortune – Develop relationships through better follow-up strategies that drive engagement. Be seen as a resource.

5. Impactful Closing Strategies – Learning to close sales is critical for success. We show you how to close sales without being “salesy” or pushy.

6. Handling Objections – Overcome objections with a proactive and strategic approach anyone can master.

7. Value-Driven Prospecting – Sales prospecting can be a challenging task. We simply the process and show you strategies that will maximize your potential with ease.

8. Creating Offers That Convert – We show you how to create high-converting offers that work as a magnet, drawing your propsecs to you and your products.

9. Negotiation Excellence – This module equips professionals with the tools and know how to master the art of negotiation. leading to win-win solutions.

10. Networking Mastery – Don’t just make new connections, create genuine connections and maximize opportunities through strategic networking.

11. Action Over Analysis – You can’t think your way to success. Success requires action. This module helps you avoid analysis paralysis and take decisive action, driving you toward your goals.

12. Motivation Methods – Learn techniques that ignite and sustain motivation in both your professional and personal life.

13. Influece Models – Embrace the principles and techniques that build influence in ways that foster trust and success.

By implementing Askology™, sales professionals, business owners, and service providers can enhance customer trust, increase conversions, and create a lasting competitive edge.

Helping Entrepreneurs and Sales Professionals Succeed:

The Askology Method™ is designed for entrepreneurs, sales professionals, consultants, and service providers who want to refine their communication strategies and win more business through authentic conversations.

“Selling isn’t about pushing products—it’s about building trust, understanding needs and providing solutions,” Kirch adds. “Askology™ helps professionals develop a consultative approach that feels natural, not forced.”

Learn More & Get Started:

The Askology Method™ is now available through online courses, training programs, and coaching. To explore the platform and access practical strategies for business growth, visit AskologyMethod.com.

Media Contact
Company Name: BOSS Academy
Contact Person: Paul Kirch
Email: Send Email
Phone: (817) 221-0638
Address:6508 Glenwick Dr
City: Fort Worth
State: TX
Country: United States
Website: https://bossacademy.com/

Telling More Stories Launches The StoryKeeper to Preserve Family Legacies

Knoxville, TN – February 11, 2025 – Telling More Stories, a company dedicated to preserving and sharing family stories, is pleased to announce the launch of The StoryKeeper, a unique service designed to keep loved ones’ legacies alive for future generations. Through a year-long series of guided interviews, The StoryKeeper transforms memories into a beautifully-written, professionally-crafted life storybook.

Telling More Stories: The StoryKeeper

“Every family has a treasure trove of stories that deserve to be heard, shared, and remembered,” said Meg Davis, the Founder of Telling More Stories. “With The StoryKeeper, we offer families an opportunity to preserve their legacy. Beyond storytelling, the service is a way to keep family bonds alive for generations.”

The StoryKeeper relies on in-depth monthly one-on-one interviews with loved ones to authentically capture their reflections, values, and life experiences. These conversations aim to unearth personal wisdom and ensure that each story is told with authenticity and respect, preserving not just facts but the unique perspectives that make each life story special. These interviews become the foundation of a comprehensive and beautifully curated legacy book that offers future generations a window into the family history.

The service includes several unique features:

  • Insightful Monthly Interviews: Families participate in guided conversations that capture personal stories and heartfelt reflections.

  • Digital Delivery: High-quality audio or video recordings of each session are delivered directly via email.

  • Printed Legacy Book: A professionally designed and bound book, up to 100 pages, complete with transcribed stories and personal photos.

  • Secure Cloud Storage: All recorded interviews are archived in a private, secure family storage system.

In a time when technology often distances people from human connection, The StoryKeeper brings people closer together through meaningful conversation and storytelling. By capturing both memories and voices, the service keeps loved ones’ legacies enduring for generations.

The StoryKeeper is available in three tiers – basic, premium, and deluxe – to accommodate different needs and budgets. To learn more about the service and to sign up, please visit https://tellingmorestories.com/.

About Telling More Stories

Telling More Stories was founded by Meg Davis, a professional author, to preserve and celebrate family legacies through guided interviews and beautifully crafted storybooks, ensuring that the voices and memories of loved ones are passed down to inspire future generations.

Socials: @‌telling_more_stories

Media Contact
Company Name: Telling More Stories
Contact Person: Meg Davis
Email: Send Email
Phone: (865) 217-6214
Country: United States
Website: https://tellingmorestories.com/

Krystal Chigbu Maka’s WOW! Serendipity Celebrates 20-Years Since Hurricane Katrina Devastated New Orleans – As Nike Holds Full-Circle Super Bowl Event at The Same Park Where She Played as a Child

WOW! Serendipity has become synonymous with fun braids at festivals, game days, and amusement parks, etc. This year marks a special milestone: a full-circle celebration at Joe Brown Park in New Orleans, where Krystal spent countless hours playing basketball as a child. It’s not just an event; it was a homecoming that honors both her roots and the strength of her beloved city after Hurricane Katrina’s devastating impact.

Houston, Texas – February 11, 2025 – Twenty years after Hurricane Katrina, New Orleans stands as a testament to resilience. The city has faced immense challenges, yet its spirit remains unbroken. The vibrant culture is alive and well. Streets once devastated are now filled with laughter and music. Community members have rallied together, rebuilding homes and hearts alike.

Krystal Chigbu Maka embodies this tenacity through WOW! Serendipity. Her hair braiding company celebrates not just style but the very essence of New Orleans’ soul. From game days to festivals, her tailored braiding styles offer joy to many while honoring local traditions. Each braid tells a story—a connection between past struggles and future triumphs.

Founded by Krystal Chigbu Maka – a wife, mother of three, and passionate community member – WOW! Serendipity began in her living room while she nursed her youngest child. Since then, it has gained popularity and most recently selected for an NFL Super Bowl event coordinated by Nike.

Nike is great at community building, and it was commendable that they made it a point to use local talent. The Full-Circle Event at Joe Brown Park was a beautiful reunion for the community. This park, a cherished backdrop of Krystal’s childhood, and central pillar for New Orleans East residents transformed into a vibrant celebration space once again.

Families and the selected high school female flag football teams gathered to partake in the events Laughter echoed through the air as the high schools indulged on familiar grounds where Krystal had spent countless hours herself. WOW! Serendipity showcased their unique flair with tailored braiding styles that drew everyone, including notable celebrities, in. Attendees enjoyed fun braids while soaking in the lively atmosphere created by flag football drills, female celebrity athletes and food vendors.

Joy radiating from each corner of the park served as a testament to resilience and unity within the New Orleans community.

WOW! Serendipity plays an essential role during significant occasions such as grand openings and church events. Their skilled braiding professionals use quality materials to craft fun braids that bring smiles to all ages.

Embracing creativity allows WOW! Serendipity to stand out. Customized braiding styles capture individual flair while bringing joy to each celebration—transforming ordinary moments into extraordinary experiences.

During a recent interview, Krystal made these comments, “We’re here to remind you that anything is attainable. What began as a creative spark on a couch has grown into a vibrant company handpicked to braid at Super Bowl events, festivals, birthday parties, corporate gatherings, carnivals, weddings, and more. From casual slumber parties to high-energy concerts, we bring not just braids, but an experience—one filled with fun, connection, and a dash of serendipity.

Our mission is simple: to make people feel amazing while inspiring them to follow their passions, no matter where they start. Whether you’re rocking our signature pigtails, French braids, or bold festival styles, each braid is a reminder that joy is in the details, and dreams can grow from anywhere—even your living room.”

For complete information, visit: https://wowserendipity.com/

Media Contact
Company Name: Serendipity Events
Contact Person: Media Relations
Email: Send Email
Phone: (323) 405-7063
City: Houston
State: TX
Country: United States
Website: wowserendipity.com/

The Wild Sonnets by Nicholas Korn Surpasses 100,000 Views on YouTube, Bringing Poetry to a Global Audience

Cincinnati, OH – February 11, 2025 – Somewhere in the fast-scrolling chaos of the internet, a quiet revolution is unfolding—one sonnet at a time. Nicholas Korn’s The Wild Sonnets YouTube channel has just crossed the 100,000-view milestone, proving that poetry isn’t just surviving in the digital age—it’s thriving. With 68 videos and counting, Korn’s readings breathe new life into the sonnet form, inviting audiences to experience poetry beyond the printed page.

Since launching the channel on April 29, 2024, Korn has built a vibrant space where literature meets performance. His signature seven-line stanza structure—part tradition, part innovation—pays homage to Shakespeare, Dickinson, and Dylan Thomas while carving its own path. The Wild Sonnets series has expanded across seven volumes, each a collection of 100 intricately crafted sonnets that blend classic style with a modern, introspective rhythm.

But this isn’t just a collection of readings. The channel is a dynamic mix of content—Korn’s interview with Classical Poets Live, a 10-minute poetry workshop, and even an award-winning animated comedy. Viewers aren’t just watching poetry; they’re stepping inside it.

“The goal has always been to make poetry an immersive experience,” says Korn. “By bringing The Wild Sonnets into a digital space, I’m inviting people to engage with poetry in a way that’s immediate, personal, and alive.”

Today, where attention spans are measured in seconds, The Wild Sonnets is breaking the mold. The channel’s growing popularity signals a hunger for art that lingers, for words that unfold and deepen with each reading. Shares and subscriptions continue to rise, proving that even in a fast-paced digital landscape, poetry still has the power to stop people in their tracks.

For those who want to hold the words in their hands, The Wild Sonnets books are available in paperback and digital editions, exclusively through BookBaby BookShop. The latest release, The Wild Sonnets: Volume VII (601-700), has already garnered critical acclaim, with features in the Boston Herald, Pittsburgh Post-Gazette, and San Diego Union-Tribune.

Step into The Wild Sonnets. Listen, reflect, and experience poetry in motion. Discover more on YouTube: https://www.youtube.com/@wildsonnets.

About Nicholas Korn

Nicholas Korn is a poet, playwright, filmmaker, and composer known for blending classical literary traditions with modern storytelling. He is the creator of The Wild Sonnets, a seven-volume poetry collection that reinvents the sonnet form with a contemporary voice. His work spans theater, film, and digital media, with projects recognized in publications like the Boston Herald and Pittsburgh Post-Gazette. Through his YouTube channel, Korn brings poetry to life, making it more accessible to audiences worldwide. His creative endeavors continue to push artistic boundaries, inviting readers and viewers into a world where language, rhythm, and meaning converge.

Media Contact
Company Name: The Wild Sonnets
Contact Person: Nicholas Korn
Email: Send Email
Country: United States
Website: https://www.youtube.com/@wildsonnets

JLS Sales Academy Announces “The Game Changer” – A Nationwide Tour to Help Insurance Agents & Financial Advisors Build Seven-Figure Businesses

Industry Leaders Will Discover Revolutionary Sales Techniques That Drive Unparalleled Growth

New Jersey – JLS Sales Academy, the powerhouse behind some of the most successful insurance agencies and financial advisory firms in the country, is launching the “Game Changer”—a multi-city, nationwide tour designed to transform the way agents and advisors do business.

This high-impact, single day event kicks off in four New Jersey cities before hitting major cities across the U.S. over a six-month period. Agents and advisors who attend will gain exclusive insights into JLS’s proven, industry-shifting strategies—methods that have taken struggling businesses and turned them into thriving, seven-figure enterprises.

At the heart of this transformational event is Jerry Smith, founder of JLS Sales Academy. Jerry built a seven-figure income as a personal producer in his early twenties, and now he’s sharing the exact six success pillars that helped him—and countless others—achieve financial freedom and long-term business success.

Why This Event Is a Game Changer

Attendees will walk away with:

  • The Six Success Pillars of Seven-Figure Wealth – Master the essential framework for rapid business growth.

  • Scenario Selling Techniques That Convert – Learn the revolutionary approach that’s proven to increase revenue and improve client retention.

  • Business Streamlining Strategies – Stop wasting time on outdated processes and implement systems that work.

  • Proven Methods to Increase Income and Client Satisfaction – Boost your bottom line while enhancing the customer experience.

“We are in the business of creating industry leaders,” says Jerry Smith. “Too many agents and advisors are grinding without seeing real financial breakthroughs. The Game Changer Event is designed to disrupt the status quo and give professionals the blueprint to earn more while working smarter.”

Who Should Attend?

This event is a must-attend for:

  • Insurance Agents & Financial Advisors ready to double or triple their income.

  • Agency Owners looking to scale their business with proven strategies.

  • New Agents eager to build a long-term, sustainable career.

  • Veteran Advisors looking for fresh, high-impact techniques to stay ahead of the competition.

The Game Changer Event is more than a seminar—it’s a movement. Agents and advisors who attend will leave with actionable steps, real-world solutions, and a roadmap to seven-figure success.

Reserve A Spot Today!

Spaces are limited. Don’t miss your opportunity to be part of this industry revolution. Visit GameChangerEvent.net to register NOW!

For media inquiries, interviews, or sponsorship opportunities, please contact:

Noreen Johnson

Team@JLSSA.com

833-481-1239

About JLS Sales Academy

JLS Sales Academy has redefined success in the Insurance and Financial Services industry. With a track record of turning struggling agents into top producers, JLS provides cutting-edge sales training, business development strategies, and a proven system to maximize income and impact.

Media Contact
Company Name: The Game Changer Tour
Contact Person: Noreen Johnson
Email: Send Email
Country: United States
Website: https://jlssa.com/

Radioligand Therapies Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Curium, Eli Lilly, Point biopharma, Fusion, Astrazeneca

The Key Radioligand Therapies Companies in the market include – Curium, Eli Lilly, Point biopharma, Fusion, Astrazeneca, and others.

 

DelveInsight’s “Radioligand Therapies Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Radioligand Therapies, historical and forecasted epidemiology as well as the Radioligand Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Radioligand Therapies, offering comprehensive insights into the Radioligand Therapies revenue trends, prevalence, and treatment landscape. The report delves into key Radioligand Therapies statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Radioligand Therapies therapies. Additionally, we cover the landscape of Radioligand Therapies clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Radioligand Therapies treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Radioligand Therapies space.

 

To Know in detail about the Radioligand Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Radioligand Therapies Market Forecast

 

Some of the key facts of the Radioligand Therapies Market Report:

  • The Radioligand Therapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In October 2024, Sanofi has collaborated with Orano Med, a subsidiary of the Orano Group and a leader in targeted alpha therapies for oncology, to combine their expertise in addressing rare cancers and accelerate the development of next-generation radioligand treatments.

  • In March 2024, Novartis has acquired Mariana Oncology, a biotechnology company focused on developing radioligand therapies (RLTs) for cancer treatment. Under the agreement, Novartis will provide an upfront payment of $1 billion, with additional potential payments of up to $750 million based on achieving predefined milestones.

  • In March 2024, AstraZeneca has announced its acquisition of Fusion Pharmaceuticals for $2 billion to advance the development of next-generation radioconjugates for cancer treatment. This acquisition enhances AstraZeneca’s expertise and strengthens its R&D, manufacturing, and supply chain capabilities in actinium-based radioconjugates.

  • In January 2024, The FDA has granted approval for Novartis’ newly automated radioligand therapy production facility for PLUVICTO, a treatment for prostate cancer

  • In January 2024, InHealth introduced the United Kingdom’s first mobile radioligand therapy service.

  • LUTATHERA generated over USD 450 million in sales during the first nine months of 2023, reflecting a 34% year-over-year growth. Novartis anticipates that LUTATHERA could surpass USD 1 billion in peak sales as a first-line therapy

  • Following its approval in 2022, PLUVICTO achieved full-year sales of USD 980 million, narrowly missing the milestone of blockbuster status in its first year on the market.

  • Eli Lilly, Curium, AstraZeneca/Fusion, and various other companies are actively involved in developing and producing radioligands, which could greatly influence and advance the Radioligand Therapy market.

  • Key Radioligand Therapies Companies: Curium, Eli Lilly, Point biopharma, Fusion, Astrazeneca, and others

  • Key Radioligand Therapies Therapies: 177Lu-PSMA-I&T, Lu-PNT2002, FPI-226, and others

  • The Radioligand Therapies market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Radioligand Therapies pipeline products will significantly revolutionize the Radioligand Therapies market dynamics.

 

Radioligand Therapies Overview

Radioligand Therapies (RLT) are a targeted cancer treatment that combines a radioactive isotope with a ligand (a molecule that binds to specific cancer cell receptors). This approach delivers radiation directly to tumor cells while minimizing damage to surrounding healthy tissue. RLT is primarily used for cancers like neuroendocrine tumors and prostate cancer, offering a promising alternative for patients with advanced or treatment-resistant disease.

 

Get a Free sample for the Radioligand Therapies Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast

 

Radioligand Therapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Radioligand Therapies Epidemiology Segmentation:

The Radioligand Therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Radioligand Therapies

  • Prevalent Cases of Radioligand Therapies by severity

  • Gender-specific Prevalence of Radioligand Therapies

  • Diagnosed Cases of Episodic and Chronic Radioligand Therapies

 

Download the report to understand which factors are driving Radioligand Therapies epidemiology trends @ Radioligand Therapies Epidemiology Forecast

 

Radioligand Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Radioligand Therapies market or expected to get launched during the study period. The analysis covers Radioligand Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Radioligand Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Radioligand Therapies Therapies and Key Companies

  • 177Lu-PSMA-I&T: Curium

  • Lu-PNT2002: Eli Lilly/Point biopharma

  • FPI-2265: Fusion/Astrazeneca

 

Discover more about therapies set to grab major Radioligand Therapies market share @ Radioligand Therapies Treatment Landscape

 

Radioligand Therapies Market Drivers

  • Rising Cancer Incidence

  • Advancements in Targeted Therapies

  • Regulatory Approvals & Expanding Indications

  • Growing Investments & Strategic Collaborations

  • Improved Manufacturing & Supply Chain Capabilities

  • Increased Research & Development

 

Radioligand Therapies Market Barriers

  • High Cost of Treatment

  • Complex Manufacturing & Supply Chain Issues

  • Limited Availability of Radiopharmaceuticals

  • Regulatory & Compliance Challenges

  • Infrastructure Limitations

  • Competition from Alternative Cancer Therapies

 

Scope of the Radioligand Therapies Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Radioligand Therapies Companies: Curium, Eli Lilly, Point biopharma, Fusion, Astrazeneca, and others

  • Key Radioligand Therapies Therapies: 177Lu-PSMA-I&T, Lu-PNT2002, FPI-226, and others

  • Radioligand Therapies Therapeutic Assessment: Radioligand Therapies current marketed and Radioligand Therapies emerging therapies

  • Radioligand Therapies Market Dynamics: Radioligand Therapies market drivers and Radioligand Therapies market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Radioligand Therapies Unmet Needs, KOL’s views, Analyst’s views, Radioligand Therapies Market Access and Reimbursement

 

To know more about Radioligand Therapies companies working in the treatment market, visit @ Radioligand Therapies Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Radioligand Therapies Market Report Introduction

2. Executive Summary for Radioligand Therapies

3. SWOT analysis of Radioligand Therapies

4. Radioligand Therapies Patient Share (%) Overview at a Glance

5. Radioligand Therapies Market Overview at a Glance

6. Radioligand Therapies Disease Background and Overview

7. Radioligand Therapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Radioligand Therapies

9. Radioligand Therapies Current Treatment and Medical Practices

10. Radioligand Therapies Unmet Needs

11. Radioligand Therapies Emerging Therapies

12. Radioligand Therapies Market Outlook

13. Country-Wise Radioligand Therapies Market Analysis (2020–2034)

14. Radioligand Therapies Market Access and Reimbursement of Therapies

15. Radioligand Therapies Market Drivers

16. Radioligand Therapies Market Barriers

17. Radioligand Therapies Appendix

18. Radioligand Therapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Radioligand Therapies Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Curium, Eli Lilly, Point biopharma, Fusion, Astrazeneca

Spinocerebellar Ataxia Market to Expand Significantly by 2034, States DelveInsight Report | Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell

The Key Spinocerebellar Ataxia Companies in the market include – Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell, and others.

 

DelveInsight’s “Spinocerebellar Ataxia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Spinocerebellar Ataxia, historical and forecasted epidemiology as well as the Spinocerebellar Ataxia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Spinocerebellar Ataxia, offering comprehensive insights into the Spinocerebellar Ataxia revenue trends, prevalence, and treatment landscape. The report delves into key Spinocerebellar Ataxia statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Spinocerebellar Ataxia therapies. Additionally, we cover the landscape of Spinocerebellar Ataxia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Spinocerebellar Ataxia treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Spinocerebellar Ataxia space.

 

To Know in detail about the Spinocerebellar Ataxia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinocerebellar Ataxia Market Forecast

 

Some of the key facts of the Spinocerebellar Ataxia Market Report:

  • The Spinocerebellar Ataxia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Steminent Biotherapeutics completed the construction of its cell therapy manufacturing facility for Stemchymal®, its pioneering stem cell-based treatment for spinocerebellar ataxia. The company intends to submit provisional drug license applications in Japan and Taiwan by 2025 to support product launches. Additionally, Steminent is preparing to file a Phase 2b clinical trial application with the FDA by 2025

  • The worldwide prevalence of spinocerebellar ataxia ranges from 1 to 5 cases per 100,000 individuals, while in Europe, it is estimated between 0.9 and 3 per 100,000. SCA3 is the most common subtype, accounting for 25% to 50% of cases, followed by SCA2 (13% to 18%), SCA6 (13% to 15%), and SCA7, in descending order of occurrence.

  • According to Bhandari et al. (2023), the global prevalence of spinocerebellar ataxia ranges from 1 to 5 per 100,000, while the overall prevalence in Europe is between 0.9 and 3 per 100,000, with regional variations such as 2 per 100,000 in Italy. Spinocerebellar Ataxia 3 is the most common type, accounting for 25% to 50% of cases, followed by Spinocerebellar Ataxia 2 (13% to 18%), Spinocerebellar Ataxia 6 (13% to 15%), and Spinocerebellar Ataxia 7.

  • Key Spinocerebellar Ataxia Companies: Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell, and others

  • Key Spinocerebellar Ataxia Therapies: Troriluzole (BHV-4157), VO659, IB1001, ROVATIRELIN, Stemchymal, and others

  • The Spinocerebellar Ataxia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinocerebellar Ataxia pipeline products will significantly revolutionize the Spinocerebellar Ataxia market dynamics.

 

Spinocerebellar Ataxia Overview

Spinocerebellar Ataxia (SCA) is a group of rare, inherited neurological disorders that cause progressive degeneration of the cerebellum and spinal cord, leading to impaired coordination, balance, and movement. It is characterized by symptoms such as unsteady gait, difficulty with fine motor skills, speech problems (dysarthria), and sometimes cognitive impairment. SCAs are caused by genetic mutations and are typically autosomal dominant, meaning they can be passed from one affected parent to their child. There are multiple subtypes (e.g., SCA1, SCA2, SCA3) with varying severity and progression rates. Currently, there is no cure, and treatment focuses on symptom management and supportive care.

 

Get a Free sample for the Spinocerebellar Ataxia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/spinocerebellar-ataxias-market

 

Spinocerebellar Ataxia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Spinocerebellar Ataxia Epidemiology Segmentation:

The Spinocerebellar Ataxia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Spinocerebellar Ataxia

  • Prevalent Cases of Spinocerebellar Ataxia by severity

  • Gender-specific Prevalence of Spinocerebellar Ataxia

  • Diagnosed Cases of Episodic and Chronic Spinocerebellar Ataxia

 

Download the report to understand which factors are driving Spinocerebellar Ataxia epidemiology trends @ Spinocerebellar Ataxia Epidemiology Forecast

 

Spinocerebellar Ataxia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinocerebellar Ataxia market or expected to get launched during the study period. The analysis covers Spinocerebellar Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinocerebellar Ataxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Spinocerebellar Ataxia Therapies and Key Companies

  • Troriluzole (BHV-4157): Biohaven

  • VO659: VICO Therapeutics

  • IB1001: IntraBio

  • ROVATIRELIN: Kissei Pharmaceutica

  • Stemchymal: Steminent/Reprocell

 

Discover more about therapies set to grab major Spinocerebellar Ataxia market share @ Spinocerebellar Ataxia Treatment Landscape

 

Spinocerebellar Ataxia Market Strengths

  • Increasing recognition of Spinocerebellar Ataxias and their impact on quality of life is driving research and development.

  • Innovative research methodologies and technologies, such as gene therapy and biomarkers, are enhancing the understanding of Spinocerebellar Ataxias.

 

Spinocerebellar Ataxia Market Drivers

  • New drug candidates in development present opportunities for breakthroughs in treatment.

  • Partnerships between academic institutions, biotech companies, and research organizations can enhance data sharing and innovation.

 

Scope of the Spinocerebellar Ataxia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Spinocerebellar Ataxia Companies: Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell, and others

  • Key Spinocerebellar Ataxia Therapies: Troriluzole (BHV-4157), VO659, IB1001, ROVATIRELIN, Stemchymal, and others

  • Spinocerebellar Ataxia Therapeutic Assessment: Spinocerebellar Ataxia current marketed and Spinocerebellar Ataxia emerging therapies

  • Spinocerebellar Ataxia Market Dynamics: Spinocerebellar Ataxia market drivers and Spinocerebellar Ataxia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Spinocerebellar Ataxia Unmet Needs, KOL’s views, Analyst’s views, Spinocerebellar Ataxia Market Access and Reimbursement

 

To know more about Spinocerebellar Ataxia companies working in the treatment market, visit @ Spinocerebellar Ataxia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Spinocerebellar Ataxia Market Report Introduction

2. Executive Summary for Spinocerebellar Ataxia

3. SWOT analysis of Spinocerebellar Ataxia

4. Spinocerebellar Ataxia Patient Share (%) Overview at a Glance

5. Spinocerebellar Ataxia Market Overview at a Glance

6. Spinocerebellar Ataxia Disease Background and Overview

7. Spinocerebellar Ataxia Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinocerebellar Ataxia

9. Spinocerebellar Ataxia Current Treatment and Medical Practices

10. Spinocerebellar Ataxia Unmet Needs

11. Spinocerebellar Ataxia Emerging Therapies

12. Spinocerebellar Ataxia Market Outlook

13. Country-Wise Spinocerebellar Ataxia Market Analysis (2020–2034)

14. Spinocerebellar Ataxia Market Access and Reimbursement of Therapies

15. Spinocerebellar Ataxia Market Drivers

16. Spinocerebellar Ataxia Market Barriers

17. Spinocerebellar Ataxia Appendix

18. Spinocerebellar Ataxia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinocerebellar Ataxia Market to Expand Significantly by 2034, States DelveInsight Report | Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell

London Apostille Services Ltd Eases Document Legalisation for UK Digital Nomads in Mexico, Including Double Taxation Relief

London Apostille Services Ltd Eases Document Legalisation for UK Digital Nomads in Mexico, Including Double Taxation Relief

London Apostille Services Ltd supports digital nomads with Mexican document legalisation

LONDON, UK – February 11, 2025 – London Apostille Services Ltd today announced the launch of a specialised document legalisation service tailored to the growing number of UK digital nomads, remote workers, freelancers, and entrepreneurs choosing Mexico as their base.

This service addresses the increasing need for authenticated documents required for visas, tax residency, business registration, employment contracts, and crucial double taxation relief applications.

Mexico’s Digital Nomad Boom and the UK-Mexico Double Taxation Agreement

Mexico’s popularity as a digital nomad destination is surging, driven by its affordable cost of living, vibrant culture, strong expat communities and the introduction of long-term visitor permits. Cities like Mexico City, Oaxaca, Puerto Escondido, Tulum, and Cancun are attracting a significant influx of remote professionals, including many from the UK.

However, working legally in Mexico, and avoiding double taxation, requires properly authenticated documents, a process that can be complex and time-consuming.

For UK citizens, the UK-Mexico Double Taxation Convention is particularly important. This agreement aims to prevent individuals and businesses from being taxed twice on the same income in both countries. To claim relief under this treaty, UK citizens often need to provide authenticated documents to the Mexican tax authorities (Servicio de Administración Tributaria, or SAT).

Comprehensive Legalisation Solutions, Including Double Taxation Documents

London Apostille Services Ltd (LAS Ltd) offers a complete suite of services designed to simplify the document authentication process for UK remote workers in Mexico:

  • Apostille Certification: Efficiently obtaining apostilles for documents originating from the UK (a Hague Convention member country), validating documents such as work contracts, tax residency certificates (e.g., forms from HMRC), and financial records. This verifies the document’s origin and the authority of the official who signed it.
  • Notarisation: Facilitating notarisation services with experienced solicitors and notaries, a requirement for some documents before legalisation by Mexican authorities.
  • Certified Translations: Providing certified Spanish translations of documents, meeting the standards of Mexican government and business entities. Translations must be performed by translators certified by the Mexican judiciary.
  • Embassy Legalisation: Managing the legalisation process for documents from countries not party to the Hague Convention (although this is less relevant for UK-origin documents).
  • Double Taxation Relief Documentation: Specifically assisting with the legalisation of documents required to claim relief under the UK-Mexico Double Taxation Convention. This may include:
    • Certificate of Residence: Issued by HMRC, confirming UK tax residency.
    • Proof of Income: Payslips, tax returns (P60, P45, Self-Assessment statements), and bank statements.
    • Company Documentation: For business owners, documents proving the company’s UK tax status.

Eliminating Risks and Ensuring Compliance

Without proper legalisation, documents may be rejected by Mexican authorities, potentially causing delays or denials for visa approvals, work permits, tax residency, business registration, or double taxation relief claims.

London Apostille Services Ltd (LAS Ltd) mitigates these risks by providing reliable and accurate authentication, enabling clients to work and live in Mexico without legal setbacks. The apostille must be issued in the official language of the issuing authority.

Real-World Examples of Succes

Case Study: Helping a UK Remote Worker Secure a Visa in Mexico

A UK-based marketing consultant relocating to Mexico City needed urgent authentication of their proof of income and employment contract for a temporary residence visa. Facing a tight submission deadline, they turned to London Apostille Services Ltd. (LAS Ltd) . The company expedited the apostille and translation process, ensuring the consultant submitted their documents on time and secured their visa without issues.

Another case involved a tech entrepreneur establishing a business in Playa del Carmen. They required legalisation of business incorporation documents, tax ID certification and financial statements. London Apostille Services Ltd facilitated the full process, ensuring compliance with Mexican business regulations.

Innovation and Client Focus

London Apostille Services Ltd (LAS Ltd) is committed to adapting to the evolving needs of the remote workforce. The company is investing in digital solutions, including an online tracking portal for real-time updates on document status. Furthermore, they are strengthening partnerships with notaries and consular offices to minimise processing times.

About London Apostille Services Ltd (LAS Ltd)

LAS Ltd is a leading provider of document authentication solutions, specialising in apostille certification, embassy legalisation, and notary/solicitor verification. The company ensures that individuals and businesses can efficiently prepare their documents for international use, adhering to the specific legal requirements of each destination country, including Mexico. Their expert team provides accurate and efficient processing. Learn more at https://apostillelondon.com.

Media Contact:

Thomas Minarik

Director

London Apostille Services Ltd

020 7050 0692

tom@apostillelondon.com

Media Contact
Company Name: London Apostille Services Ltd.
Contact Person: Thomas Minarik
Email: Send Email
Country: United States
Website: https://apostillelondon.com

Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmac

“Allergic Rhinitis Market 2034”
The Allergic Rhinitis market growth is driven by factors like increase in the prevalence of Allergic Rhinitis, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Allergic Rhinitis market report also offers comprehensive insights into the Allergic Rhinitis market size, share, Allergic Rhinitis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Allergic Rhinitis market size growth forward.

Some of the key highlights from the Allergic Rhinitis Market Insights Report:

  • Several key pharmaceutical companies, including Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others, are developing novel products to improve the Allergic Rhinitis treatment outlook.

  • In November 2024, Keymed Biosciences Co. Ltd. initiated a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of Stapokibart injection in patients with allergic rhinitis. Allergic rhinitis (AR) is a chronic inflammatory condition of the nasal mucosa, primarily mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

  • In the same month, Wecare Probiotics Co. Ltd. began a study to assess the effectiveness of Weizmannia Coagulans BC99 in alleviating allergic rhinitis symptoms in adults. The study also aims to evaluate its impact on the gut microbiota and its potential to reduce adverse reactions in patients.

  • In 2023, the United States had the largest Allergic Rhinitis market size among the 7MM, valued at approximately USD 3,600 million, with projections indicating further growth by 2034.

  • Japan recorded the highest prevalence of Allergic Rhinitis among the 7MM in 2023, with around 65 million cases, a number expected to rise by 2034.

  • The emerging drug REGN5713-5714-5715 is anticipated to launch in EU4 and the UK by 2025, followed by Japan in 2026, offering potential relief and reducing the disease burden in the coming years.

  • As per DelveInsight analysis, the Allergic Rhinitis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Allergic Rhinitis Market Landscape

Allergic Rhinitis Overview

Allergic rhinitis is an atopic condition characterized by sneezing, nasal congestion, clear rhinorrhea, and nasal itching. It involves an IgE-mediated immune response to inhaled allergens in the immediate phase, followed by a leukotriene-mediated late phase. Proper evaluation and treatment are essential, with an interprofessional team playing a crucial role in improving patient care.

The condition is classified based on the triggering allergen (seasonal, perennial, or episodic), symptom frequency (intermittent or persistent), and severity (ranging from mild to severe).

Risk factors include exposure to pollen (trees, grass, and weeds like ragweed), indoor allergens (dust mites, pet dander), proteins, chemicals, antibiotic use, air pollution, farm animals (in LMICs), household pets, parental smoking, and intense physical activity in adolescents.

Common symptoms include rhinorrhea, nasal itching, sneezing, and congestion, often accompanied by allergic conjunctivitis, itchy ears and palate, and asthma. Diagnosis is typically supported by a correlation between clinical history and allergen sensitization.

Do you know the treatment paradigms for different countries? Download our Allergic Rhinitis Market Sample Report

Allergic Rhinitis Epidemiology Insights

  • According to DelveInsight’s assessment, the total estimated diagnosed prevalent cases of allergic rhinitis in the 7MM were approximately 90 million in 2023.

Allergic Rhinitis Epidemiology Segmentation

DelveInsight’s Allergic Rhinitis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Allergic Rhinitis historical patient pools and forecasted Allergic Rhinitis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Allergic Rhinitis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Allergic Rhinitis Prevalence

  • Age-Specific Allergic Rhinitis Prevalence

  • Gender-Specific Allergic Rhinitis Prevalence

  • Diagnosed and Treatable Cases of Allergic Rhinitis

Visit for more @ Allergic Rhinitis Epidemiological Insights

Allergic Rhinitis Market Outlook

The primary goal in treating allergic rhinitis is to alleviate symptoms. Treatment options to achieve this include avoidance of allergens, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combined intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy.

A full range of pharmacological treatments for allergic rhinitis includes both FDA-approved and off-label options. For mild cases, nasal washes can help clear mucus. Off-label treatments such as antihistamines are effective for occasional symptoms and can also be used as nasal sprays. Corticosteroid nasal sprays are the most effective treatment and work best with continuous use, although they are also useful for shorter or intermittent periods. These sprays are safe for both children and adults and come in various prescription and off-label brands. Decongestants can also help alleviate nasal congestion.

Additional treatments include leukotriene inhibitors, which block chemicals that trigger symptoms. Immunotherapy, including allergy shots, may be recommended for more challenging symptoms, offering regular doses of allergens to help the body adjust. Sublingual Immunotherapy Treatment (SLIT), which involves placing medicine under the tongue, can also be effective for grass and ragweed allergies.

Allergic Rhinitis Marketed Drugs

  • RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.

Allergic Rhinitis Emerging Drugs

  • REGN5713-5714-5715: Regeneron Pharmaceuticals

  • Grass MATA MPL: Allergy Therapeutics

Allergic Rhinitis Key Companies

  • Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others

For more information, visit Allergic Rhinitis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Allergic Rhinitis Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Allergic Rhinitis, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Allergic Rhinitis epidemiology in the 7MM

  • Allergic Rhinitis marketed and emerging therapies

  • Allergic Rhinitis companies

  • Allergic Rhinitis market drivers and barriers

Table of Contents:

1 Allergic Rhinitis Market Key Comprehensive Insights

2 Allergic Rhinitis Market Report Introduction

3 Competitive Intelligence Analysis for Allergic Rhinitis

4 Allergic Rhinitis Market Analysis Overview at a Glance

5 Executive Summary of Allergic Rhinitis

6 Allergic Rhinitis Epidemiology and Market Methodology

7 Allergic Rhinitis Epidemiology and Patient Population

8 Allergic Rhinitis Patient Journey

9 Allergic Rhinitis Treatment Algorithm, Allergic Rhinitis Current Treatment, and Medical Practices

10 Key Endpoints in Allergic Rhinitis Clinical Trials

11 Allergic Rhinitis Marketed Therapies

12 Allergic Rhinitis Emerging Therapies

13 Allergic Rhinitis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Allergic Rhinitis

16 Allergic Rhinitis Market Key Opinion Leaders Reviews

18 Allergic Rhinitis Market Drivers

19 Allergic Rhinitis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Allergic Rhinitis Epidemiology 2034

DelveInsight’s “Allergic Rhinitis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Allergic Rhinitis Pipeline 2024

“Allergic Rhinitis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Allergic Rhinitis market. A detailed picture of the Allergic Rhinitis pipeline landscape is provided, which includes the disease overview and Allergic Rhinitis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmac

Alcohol Use Disorder Market Growth Projections 2024-2034: DelveInsight Analysis | Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas

The Key Alcohol Use Disorder Companies in the market include – Corcept Therapeutics, Adial Pharmaceuticals, MediciNova, Clearmind Medicine, Bioprojet, Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others.

 

The Alcohol Use Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alcohol Use Disorder pipeline products will significantly revolutionize the Alcohol Use Disorder market dynamics.

 

DelveInsight’s “Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Alcohol Use Disorder, historical and forecasted epidemiology as well as the Alcohol Use Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Alcohol Use Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Alcohol Use Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alcohol Use Disorder Market Forecast

 

Some of the key facts of the Alcohol Use Disorder Market Report:

  • The Alcohol Use Disorder market size was valued ~USD 620 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In November 2024, Adial Pharmaceuticals received a patent from the United States Patent and Trademark Office, covering an expanded range of genotype combinations identified through its proprietary genetic diagnostic for the targeted treatment of AUD with AD04, its lead investigational drug. Additionally, in the same month, the company reported positive topline results from the pharmacokinetics (PK) study of AD04, which will aid in refining the study design for the upcoming Phase 3 clinical trial.

  • In August 2024, Adial Pharmaceuticals partnered with Boudicca to support the development of technical and regulatory strategies for its companion diagnostic genetic test.

  • In July 2024, Adial Pharmaceuticals filed a new patent application for AD04, aimed at treating Alcohol Use Disorder, which, if approved, could secure protection for its key assets until at least 2044. In the same month, the company progressed to the second cohort in its pharmacokinetics study of AD04 for AUD.

  • In July 2024, The US FDA approved the IND application for the CMND-100 oral capsule, allowing the company to commence a Phase I/IIa clinical trial in the US for Alcohol Use Disorder (AUD). Additionally, Clearmind Medicine formed a strategic partnership with JS First Sdn. Bhd. to identify global manufacturers and distributors for its MEAI-based alcohol substitute beverages, supporting its international expansion. In June 2024, Adial Pharmaceuticals published the previously reported findings from its Phase III ONWARD study in the *European Journal of Internal Medicine*.

  • Among the 7MM countries the highest Alcohol Use Disorder market size was in the United States accounting for ~USD 475 million in 2023.

  • According to DelveInsight’s estimates, Germany had the largest AUD market among the EU4 and the UK in 2023, with nearly USD 36.5 million, followed by the UK with approximately USD 26.6 million. Spain had the smallest market, at around USD 19.3 million.

  • According to DelveInsight’s analysis, there were approximately 25,312,290 diagnosed prevalent cases of AUD in the 7MM over a 12-month period in 2023, and this number is expected to rise by 2034.

  • Based on DelveInsight’s analysis, the US accounted for approximately 58.68% of the total 12-month diagnosed prevalent cases of AUD in the 7MM in 2023, and this figure is expected to increase by 2034.

  • DelveInsight’s epidemiology model for AUD indicates a male predominance in the 7MM, with an estimated 9,354,525 male cases and 5,498,643 female cases in the US in 2023.

  • In 2023, Germany had the highest number of 12-month diagnosed prevalent cases of AUD among the EU4 and the UK, with approximately 2,532,809 cases, whereas Spain had the lowest, with nearly 1,338,496 cases. These numbers are expected to rise by 2034.

  • In 2023, the 12-month diagnosed prevalent population of AUD in Japan was approximately 1,156,355 cases, with this number expected to change over the study period (2020–2034).

  • The AUD market includes a variety of off-label and generic medications such as gabapentin, varenicline, benzodiazepines, memantine, ondansetron, aripiprazole, and suvorexant, in addition to four FDA-approved medication-assisted treatments: Acamprosate, ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone). Furthermore, TOPAMAX (topiramate) is recommended by the National Institute on Alcohol Abuse and Alcoholism for AUD treatment.

  • Key Alcohol Use Disorder Companies: Corcept Therapeutics, Adial Pharmaceuticals, MediciNova, Clearmind Medicine, Bioprojet, Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others

  • Key Alcohol Use Disorder Therapies: CORT 118335 (miricorilant), AD04 (ondansetron), MN-166 (ibudilast), CMND-100, BP1.3656, Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others

  • The Alcohol Use Disorder epidemiology based on gender analyzed that males are more affected with Alcohol Use Disorder (AUD) as compared to females

 

Alcohol Use Disorder Overview

Alcohol Use Disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol consumption despite adverse social, occupational, or health consequences. It encompasses a range of drinking behaviors, from mild to severe, and is sometimes referred to as alcoholism.

 

Get a Free sample for the Alcohol Use Disorder Market Report:

https://www.delveinsight.com/report-store/alcohol-use-disorder-market

 

Alcohol Use Disorder Market

The dynamics of the Alcohol Use Disorder market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“Alcohol use disorders are an important cause of morbidity and mortality. Despite the National Institute on Alcohol Abuse and Alcoholism (NIAAA) recommendations that medications be considered for patients with alcohol dependence, the mainstay of treatment has been counseling”

 

Alcohol Use Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Alcohol Use Disorder Epidemiology Segmentation:

The Alcohol Use Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Alcohol Use Disorder

  • Prevalent Cases of Alcohol Use Disorder by severity

  • Gender-specific Prevalence of Alcohol Use Disorder

  • Diagnosed Cases of Episodic and Chronic Alcohol Use Disorder

 

Download the report to understand which factors are driving Alcohol Use Disorder epidemiology trends @ Alcohol Use Disorder Epidemiological Insights

 

Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alcohol Use Disorder market or expected to get launched during the study period. The analysis covers Alcohol Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alcohol Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Alcohol Use Disorder treatment, visit @ Alcohol Use Disorder Medications

 

Alcohol Use Disorder Therapies and Key Companies

  • CORT 118335 (miricorilant): Corcept Therapeutics

  • MN-166 (ibudilast): MediciNova

  • CMND-100: Clearmind Medicine

  • BP1.3656: Bioprojet

  • Pear-009: Pear Therapeutics

  • CYB003: Cybin

  • Nezavist: Lohocla Research

  • BXCL501: BioXcel Therapeutics

  • PT150: Pop Test Oncology

  • DCR-AUD: Dicerna Pharmaceuticals

  • ASP8062: Astellas Pharma

  • KT 110: Kinnov Therapeutics

  • Ibudilast: MediciNova

  • AD04 : Adial Pharmaceuticals

 

Alcohol Use Disorder Pipeline Market Drivers

  • Increasing Awareness

  • Increasing research and development

  • Initiative taken by market players

 

Alcohol Use Disorder Pipeline Market Barriers

  • Less Treatment Utilization

  • Side Effects of the Current Alcohol Use Disorder Therapies

 

Scope of the Alcohol Use Disorder Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Alcohol Use Disorder Companies: Corcept Therapeutics, Adial Pharmaceuticals, MediciNova, Clearmind Medicine, Bioprojet, Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others

  • Key Alcohol Use Disorder Therapies: CORT 118335 (miricorilant), AD04 (ondansetron), MN-166 (ibudilast), CMND-100, BP1.3656, Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others

  • Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and Alcohol Use Disorder emerging therapies

  • Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and Alcohol Use Disorder market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Alcohol Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Alcohol Use Disorder Market Access and Reimbursement

 

Discover more about therapies set to grab major Alcohol Use Disorder market share @ Alcohol Use Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Alcohol Use Disorder Market Report Introduction

2. Executive Summary for Alcohol Use Disorder

3. SWOT analysis of Alcohol Use Disorder

4. Alcohol Use Disorder Patient Share (%) Overview at a Glance

5. Alcohol Use Disorder Market Overview at a Glance

6. Alcohol Use Disorder Disease Background and Overview

7. Alcohol Use Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Alcohol Use Disorder

9. Alcohol Use Disorder Current Treatment and Medical Practices

10. Alcohol Use Disorder Unmet Needs

11. Alcohol Use Disorder Emerging Therapies

12. Alcohol Use Disorder Market Outlook

13. Country-Wise Alcohol Use Disorder Market Analysis (2020–2034)

14. Alcohol Use Disorder Market Access and Reimbursement of Therapies

15. Alcohol Use Disorder Market Drivers

16. Alcohol Use Disorder Market Barriers

17. Alcohol Use Disorder Appendix

18. Alcohol Use Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alcohol Use Disorder Market Growth Projections 2024-2034: DelveInsight Analysis | Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas